Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2 : A Prospective, Multicenter Study
INTRODUCTION: Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings. We aimed to evaluate the safety and efficacy of sofosbuvir/velpatasvir for decompensated cirrhotic patients with genotypes 1 and 2 in real-world clinical practice.
METHODS: A prospective, multicenter study of 12-week sofosbuvir/velpatasvir was conducted for patients with decompensated cirrhosis at 33 institutions.
RESULTS: The cohort included 71 patients (52 genotype 1, 19 genotype 2): 7 with Child-Pugh class A, 47 with class B, and 17 with class C (median score 8; range 5-13). The albumin-bilirubin (ALBI) score ranged from - 3.01 to - 0.45 (median - 1.58). Sixty-nine patients (97.2%) completed treatment as scheduled. The overall rate of sustained virologic response at 12 weeks post-treatment (SVR12) was 94.4% (67/71). SVR12 rates in the patients with Child-Pugh classes A, B, and C were 85.7%, 97.9%, and 88.2%, respectively. Among 22 patients with a history of hepatocellular carcinoma treatment, 20 (90.9%) achieved SVR12. The Child-Pugh score and ALBI grade significantly improved after achieving SVR12 (p = 7.19 × 10-4 and 2.42 × 10-4, respectively). Notably, the use of diuretics and branched-chain amino acid preparations significantly reduced after achieving SVR12. Adverse events were observed in 19.7% of the patients, leading to treatment discontinuation in two patients with cholecystitis and esophageal varices rupture, respectively.
CONCLUSION: Twelve weeks of sofosbuvir/velpatasvir in real-world clinical practice yielded high SVR rates and acceptable safety profiles in decompensated cirrhotic patients with genotypes 1 and 2. Achievement of SVR not only restored the liver functional reserve but also reduced or spared the administration of drugs for related complications.
TRIAL REGISTRATION: UMIN registration no, 000038587.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Infectious diseases and therapy - 9(2020), 4 vom: 08. Dez., Seite 851-866 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Atsukawa, Masanori [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ALBI grade |
|---|
| Anmerkungen: |
Date Revised 20.08.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1007/s40121-020-00329-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314702113 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314702113 | ||
| 003 | DE-627 | ||
| 005 | 20231225153312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40121-020-00329-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1048.xml |
| 035 | |a (DE-627)NLM314702113 | ||
| 035 | |a (NLM)32897520 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Atsukawa, Masanori |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2 |b A Prospective, Multicenter Study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.08.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a INTRODUCTION: Clinical trials of direct-acting antivirals for patients with decompensated cirrhosis have been conducted, but there is limited information on the medicinal applications in clinical settings. We aimed to evaluate the safety and efficacy of sofosbuvir/velpatasvir for decompensated cirrhotic patients with genotypes 1 and 2 in real-world clinical practice | ||
| 520 | |a METHODS: A prospective, multicenter study of 12-week sofosbuvir/velpatasvir was conducted for patients with decompensated cirrhosis at 33 institutions | ||
| 520 | |a RESULTS: The cohort included 71 patients (52 genotype 1, 19 genotype 2): 7 with Child-Pugh class A, 47 with class B, and 17 with class C (median score 8; range 5-13). The albumin-bilirubin (ALBI) score ranged from - 3.01 to - 0.45 (median - 1.58). Sixty-nine patients (97.2%) completed treatment as scheduled. The overall rate of sustained virologic response at 12 weeks post-treatment (SVR12) was 94.4% (67/71). SVR12 rates in the patients with Child-Pugh classes A, B, and C were 85.7%, 97.9%, and 88.2%, respectively. Among 22 patients with a history of hepatocellular carcinoma treatment, 20 (90.9%) achieved SVR12. The Child-Pugh score and ALBI grade significantly improved after achieving SVR12 (p = 7.19 × 10-4 and 2.42 × 10-4, respectively). Notably, the use of diuretics and branched-chain amino acid preparations significantly reduced after achieving SVR12. Adverse events were observed in 19.7% of the patients, leading to treatment discontinuation in two patients with cholecystitis and esophageal varices rupture, respectively | ||
| 520 | |a CONCLUSION: Twelve weeks of sofosbuvir/velpatasvir in real-world clinical practice yielded high SVR rates and acceptable safety profiles in decompensated cirrhotic patients with genotypes 1 and 2. Achievement of SVR not only restored the liver functional reserve but also reduced or spared the administration of drugs for related complications | ||
| 520 | |a TRIAL REGISTRATION: UMIN registration no, 000038587 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ALBI grade | |
| 650 | 4 | |a Child–Pugh class | |
| 650 | 4 | |a Decompensated cirrhosis | |
| 650 | 4 | |a Hepatitis C virus | |
| 650 | 4 | |a Sofosbuvir | |
| 650 | 4 | |a Velpatasvir | |
| 700 | 1 | |a Tsubota, Akihito |e verfasserin |4 aut | |
| 700 | 1 | |a Kondo, Chisa |e verfasserin |4 aut | |
| 700 | 1 | |a Toyoda, Hidenori |e verfasserin |4 aut | |
| 700 | 1 | |a Nakamuta, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Takaguchi, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Watanabe, Tsunamasa |e verfasserin |4 aut | |
| 700 | 1 | |a Hiraoka, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Uojima, Haruki |e verfasserin |4 aut | |
| 700 | 1 | |a Ishikawa, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Iwasa, Motoh |e verfasserin |4 aut | |
| 700 | 1 | |a Tada, Toshifumi |e verfasserin |4 aut | |
| 700 | 1 | |a Nozaki, Akito |e verfasserin |4 aut | |
| 700 | 1 | |a Chuma, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Fukunishi, Shinya |e verfasserin |4 aut | |
| 700 | 1 | |a Asai, Akira |e verfasserin |4 aut | |
| 700 | 1 | |a Asano, Toru |e verfasserin |4 aut | |
| 700 | 1 | |a Ogawa, Chikara |e verfasserin |4 aut | |
| 700 | 1 | |a Abe, Hiroshi |e verfasserin |4 aut | |
| 700 | 1 | |a Hotta, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Shima, Toshihide |e verfasserin |4 aut | |
| 700 | 1 | |a Iio, Etsuko |e verfasserin |4 aut | |
| 700 | 1 | |a Mikami, Shigeru |e verfasserin |4 aut | |
| 700 | 1 | |a Tachi, Yoshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Fujioka, Shinichi |e verfasserin |4 aut | |
| 700 | 1 | |a Okubo, Hironao |e verfasserin |4 aut | |
| 700 | 1 | |a Shimada, Noritomo |e verfasserin |4 aut | |
| 700 | 1 | |a Tani, Joji |e verfasserin |4 aut | |
| 700 | 1 | |a Hidaka, Isao |e verfasserin |4 aut | |
| 700 | 1 | |a Moriya, Akio |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Kunihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Akahane, Takehiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamashita, Naoki |e verfasserin |4 aut | |
| 700 | 1 | |a Okubo, Tomomi |e verfasserin |4 aut | |
| 700 | 1 | |a Arai, Taeang |e verfasserin |4 aut | |
| 700 | 1 | |a Morita, Kiyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawata, Kazuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Tanaka, Yasuhito |e verfasserin |4 aut | |
| 700 | 1 | |a Okanoue, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Shin |e verfasserin |4 aut | |
| 700 | 1 | |a Kumada, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Iwakiri, Katsuhiko |e verfasserin |4 aut | |
| 700 | 0 | |a KTK49 Liver Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d 2012 |g 9(2020), 4 vom: 08. Dez., Seite 851-866 |w (DE-627)NLM240483693 |x 2193-8229 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:4 |g day:08 |g month:12 |g pages:851-866 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40121-020-00329-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 4 |b 08 |c 12 |h 851-866 | ||